Table 4.

Univariate survival analysis of LARC.

Factors	n	5-year DFS	x2	P	5-yesar OS	x2	P
Tumor Size			1.213	0.271		1.693	0.193
≥ 5 cm	36	20 (55.6%)			24 (66.7%)
< 5 cm	44	19 (43.2%)			23 (52.3%)
Differentiation Degree			0.572	0.751		1.111	0.574
High	21	10 (47.6%)			11 (52.4%)
Medium	40	21 (52.5%)			23 (57.5%)
Low	19	8 (42.1%)			13 (68.4%)
Distance to the anal margin			1.357	0.244		0.823	0.364
≤ 5 cm	34	14 (41.2%)			18 (52.9%)
> 5 cm	46	25 (54.3%)			29 (63.0%)
Clinical T staging			20.608	<0.001		13.179	<0.001
cT3	31	25 (80.6%)			26 (83.9%)
cT4	49	14 (28.6%)			21 (42.9%)
Pathological T staging			16.540	<0.001		13.316	<0.001
pT0~2	19	17 (89.5%)			18 (94.7%)
pT3~4	61	22 (36.1%)			29 (47.5%)
Clinical N staging			31.223	<0.001		28.193	<0.001
cN0	38	31 (81.6%)			34 (89.5%)
cN+	42	8 (19%)			13 (31.0%)
Pathological N staging			25.379	<0.001		27.600	<0.001
pN0	47	34 (72.3%)			39 (83.0%)
pN+	33	5 (15.2%)			8 (24.2%)
CEA (ng/ml)			1.787	0.181		3.449	0.063
< 5	39	22 (56.4%)			27 (69.2%)
≥ 5	41	17 (41.5%)			20 (48.8%)
RUNX3			32.494	<0.001		25.532	<0.001
High expression	25	24 (96.0%)			25 (100.0%)
Low expression	55	15 (27.30%)			22 (40.00%)
EZH2			26.502	<0.001		30.397	<0.001
High expression	44	10 (22.70%)			12 (35.30%)
Low expression	36	29 (80.60%)			35 (97.20%)